Application of Glatiramer Acetate to Neurodegenerative Diseases beyond Multiple Sclerosis: The Need for Disease-Specific Approaches

Author： Schwartz Michal Bukshpan Shay Kunis Gilad

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.22, Iss.5, 2008-01, pp. : 293-299

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis

By Simpson D. Noble S. Perry C.

BioDrugs, Vol. 17, Iss. 3, 2003-01 ,pp. : 207-210

Adis International

Access to resources Recommend Favorite

Localized Panniculitis and Subsequent Lipoatrophy with Subcutaneous Glatiramer Acetate (Copaxone ® ) Injection for the Treatment of Multiple Sclerosis

By Noemi Soós Kaweh Shakery Ulrich Mrowietz

American Journal of Clinical Dermatology, Vol. 5, Iss. 5, 2004-01 ,pp. : 357-359

Adis International

Access to resources Recommend Favorite

Improving career re-entry outcomes for people with multiple sclerosis: a comparison of two approaches

By Rumrill P.D. Roessler R.T. Cook B.G.

Journal of Vocational Rehabilitation, Vol. 10, Iss. 3, 1998-06 ,pp. : 241-252

Elsevier

Access to resources Recommend Favorite

Therapeutic Approaches to Multiple Sclerosis: An Update on Failed, Interrupted, or Inconclusive Trials of Neuroprotective and Alternative Treatment Strategies

By Meuth Sven G. Bittner Stefan

BioDrugs, Vol. 24, Iss. 5, 2010-10 ,pp. : 317-330

Adis International

Access to resources Recommend Favorite

Therapeutic Approaches to Multiple Sclerosis: An Update on Failed, Interrupted, or Inconclusive Trials of Immunomodulatory Treatment Strategies

By Ulzheimer Jochen C. Meuth Sven G. Bittner Stefan

BioDrugs, Vol. 24, Iss. 4, 2010-08 ,pp. : 249-274

Adis International

Access to resources Recommend Favorite